8-K current report · filed Nov 16, 2026

Lexeo Therapeutics, Inc. (LXEO) 8-K Current Report: November 16, 2026

Item 2.02Item 7.01Item 8.01Item EX-99.1Item EX-99.2Item EX-99.3LXEO overview

Short answer

Lexeo Therapeutics, Inc. (LXEO) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3). Press release covers Lexeo’s business highlights and financial results for the three and nine months ended September 30, 2026.

Lexeo Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release covers Lexeo’s business highlights and financial results for the three and nine months ended September 30, 2026
  • Investors should review Exhibit 99.1 for earnings figures, cash position, pipeline updates and forward operating implications

Item 7.01 · Regulation FD Disclosure

  • Corporate presentation attached as Exhibit 99.2 for the referenced webcast
  • Investor relevance depends on pipeline, clinical, regulatory, or financing updates in the presentation

Item 8.01 · Other Events

  • Positive interim Phase I/II data announced for LX2020 targeting PKP2-associated arrhythmogenic cardiomyopathy
  • Regulatory updates for LX2020 create potential development-pathway implications
  • Investor conference call and webcast scheduled for November 16, 2026 at 8:00 a.m. ET
  • Updated corporate presentation posted, supporting ongoing investor and analyst outreach

Item EX-99.1 · Exhibit EX-99.1

  • High-dose LX2020 cohorts showed 80% mean NSVT reduction and 44% mean PVC reduction at latest assessment, supporting clinical proof-of-concept
  • FDA openness to NSVT as a primary surrogate endpoint strengthens potential accelerated-approval pathway, with pivotal design expected in 1H 2027
  • Safety generally favorable across 10 participants, though liver-test elevations and one Grade 3 ventricular tachycardia event remain monitoring considerations
  • Cash, cash equivalents and investments of $219.1 million expected to fund operations into 2028, reducing near-term financing pressure
  • Q3 net loss widened to $38.3 million from $20.3 million, while R&D expense rose to $34.5 million from $15.7 million due partly to acquisition and milestone costs

Item EX-99.2 · Exhibit EX-99.2

  • Phase 1/2 HEROIC-PKP2 interim data: high-dose LX2020 reduced mean NSVT 80% and PVC burden 44% at latest assessment, n=7
  • Five of seven high-dose participants reported symptom improvement, while cardiac MRI showed stabilization or improvement in most participants
  • Safety profile generally favorable across 10 participants, with no clinically significant complement activation or study discontinuations
  • FDA open to guideline-defined NSVT as a potential accelerated-approval surrogate endpoint
  • Pivotal-study design expected in 1H 2027, with initiation targeted for 2H 2027

Item EX-99.3 · Exhibit EX-99.3

  • Corporate overview highlights LX2006 as Lexeo’s lead FA-cardiomyopathy asset, with potential first disease-modifying gene therapy in a high-unmet-need market
  • SUNRISE-FA 2 pivotal study initiated June 2026, enrolling 26 participants with 13 treated at 1.2×10¹² vg/kg
  • Topline SUNRISE-FA 2 data expected 2H 2027, with potential accelerated-approval BLA submission targeted for 1H 2028
  • Phase I/II data showed approximately 18% LVMi reduction at 6 months, rising to approximately 28% in higher-dose cohorts
  • Lexeo projects cash runway into 2028, supporting execution through pivotal data and potential regulatory filing catalysts

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Lexeo Therapeutics, Inc. 8-K filings

Get the next LXEO 8-K as it lands

Follow LXEO for push alerts, or ask the research agent what this filing means.